Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.33 |
| ▸ | LCAT | P04180 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30276678 | 1.00 | RXRA (0.35) | RXRAGRIN1GRIN2BHCRTR1HCRTR2 | |
| SCHEMBL25414850 | 0.77 | NR1H2 (0.31) | RXRAGRIN1GRIN2BLCAT | |
| SCHEMBL29437675 | 0.77 | NR1H2 (0.31) | RXRAGRIN1GRIN2BLCAT | |
| SCHEMBL30276132 | 0.73 | GRM2 (0.35) | HCRTR1HCRTR2LCAT | |
| SCHEMBL31749086 | 0.71 | HCRTR1 (0.36) | HCRTR1HCRTR2OGA | |
| SCHEMBL24920785 | 0.68 | ALKBH1 (0.41) | RXRAGRIN1GRIN2BHCRTR1HCRTR2 | |
| SCHEMBL30508619 | 0.67 | TSHR (0.42) | — | |
| SCHEMBL16547539 | 0.66 | NPSR1 (0.43) | HCRTR1HCRTR2OGA | |
| SCHEMBL16543484 | 0.66 | ALKBH1 (0.40) | RXRAGRIN1GRIN2BHCRTR1HCRTR2 | |
| SCHEMBL24920801 | 0.65 | HCRTR1 (0.40) | HCRTR1HCRTR2OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295123-A1 | NOVEL IMIDAZOLE-PYRAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4208454-A1 | IMIDAZOLE-PYRAZOLE DERIVATIVES WITH ANTI-BACTERIAL PROPERTIES | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| CN-115989227-A | Imidazole-pyrazole derivatives having antibacterial properties | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
| WO-2022049011-A1 | IMIDAZOLE-PYRAZOLE DERIVATIVES WITH ANTI-BACTERIAL PROPERTIES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295123-A1 | NOVEL IMIDAZOLE-PYRAZOLE DERIVATIVES | CYP3A7, NISCH, ARG1 | RXRA 2931/4885GRIN1 3451/4885GRIN2B 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.